Introduction {#S1}
============

Phosphatidylinositol (and its phosphorylated derivatives) and CL are two anionic phospholipids that perform a plethora of essential functions in cells. Both lipids are relatively minor lipids (less than 10% of total lipids) but have complex functions. The synthesis of both lipids requires the liponucleotide, CDP-DAG. CDP-DAG is synthesized from PA and CTP, and the reaction is catalyzed by enzymes that display CDP-DAG synthase activities. Despite sharing a common precursor, CDP-DAG, the synthesis of PI occurs at the endoplasmic reticulum (ER) whilst CL is synthesized in the mitochondria ([Figure 1](#F1){ref-type="fig"}).

![Synthesis of phosphatidylinositol (PI) at the ER and of cardiolipin (CL) in mitochondria. PA, in the ER, is converted to CDP-DAG via the CDS enzymes. CDP-DAG is used by PIS, to synthesize PI. PA can be transferred from the ER to mitochondria, where it is transported across the OMM and IMS to the IMM. Here, TAMM41 utilizes PA to make CDP-DAG, then PGP via PGPS, and PG via PTPMT1. Finally, CL is made by CLS using PG and another molecule of CDP-DAG. It could be the case the CDP-DAG is transported across the cytosol from the ER to mitochondria, where it can be utilized for CL synthesis as discussed in the text. PA, phosphatidic acid; PIS, PI synthase; TAMM41, enzyme with CDS activity; PGPS, phosphatidylglycerolphosphate synthase; CLS, cardiolipin synthase; PI, phosphatidylinositol; CDP-DAG, CDP-diacylglycerol; PGP, phosphatidylglycerol phosphate; PTPMT1, protein tyrosine phosphatase mitochondrial 1; PG, phosphatidylglycerol; CL, cardiolipin; MAM, mitochondrial associated membranes; OMM, outer mitochondrial membrane; IMS, inner mitochondrial space; IMM, inner mitochondrial membrane.](fcell-08-00063-g001){#F1}

The importance of PI, in part, derives from its inositol ring as well as from its acyl chain composition. The inositol ring of PI can be phosphorylated at three positions, either singly or in combination, resulting in seven derivatives. Many of the phosphorylated PIs, including PI(4,5)P~2~, provide docking sites for reversible recruitment of proteins to membranes and to regulate protein function ([@B29]; [@B10]; [@B22]; [@B128]). Many transmembrane proteins, including ion channels and G-protein-coupled receptors, are known to be bound to PI(4,5)P~2~, which regulates their activity ([@B56]; [@B163]; [@B130]). PI(4,5)P~2~ is also a substrate for two signaling enzymes, PLC, and PI3K ([@B154]; [@B24]). PI(4)P has important roles in membrane trafficking ([@B26]), as well as being utilized by many lipid transporters as a counter transport molecule. This allows movement of cholesterol or PS from the ER to other organelles, including the PM ([@B23]; [@B107]). The acyl chain composition of PI and its phosphorylated derivatives are also unique. Most phospholipids contain a variety of acyl chains, varying in length as well as in the number of double bonds. Phosphoinositides are atypical; the main acyl chains present are C18:0 (stearic acid) at the *sn*-1 position and C20:4 (arachidonic acid) at the *sn*-2 position ([@B82]; [@B5]; [@B113]; [@B153]; [@B109]; [@B11]; [@B13]). However, cultured cell-lines are more variable in their acyl chain composition ([@B113]; [@B153]). PI can attain its distinctive acyl chain composition during its synthesis and also through acyl chain remodeling after its synthesis ([@B64]; [@B82]; [@B5]; [@B58]).

Like PI, CL is unique compared to all other phospholipids, and it is the signature lipid of mitochondria. CL is essentially a lipid dimer with four acyl chains. The phosphate groups of two PA moieties are connected with a glycerol backbone to form a dimeric structure ([@B99]). Like PI, the fatty acid profile of CL can also be quite specific. Tissues such as heart and skeletal muscle, require high mitochondrial metabolic activity and are greatly enriched in tetra-linoleoyl-CL ((C18:2)~4~-CL). The C18:2 acyl chains are acquired after its synthesis by acyl chain remodeling by tafazzin, a CoA-independent phospholipid acyltransferase ([@B139]). Similar to PI and its derivatives, CL has a plethora of functions mainly confined to mitochondria. By associating with the major proteins of the mitochondrial respiratory chain, CL increases the efficiency of electron flow and ATP/ADP exchange. CL is also required for the electron transport chain super-complex formation, maintenance of cristae morphology, mitophagy and facilitating mitochondrial fission/fusion ([@B1]; [@B33]; [@B60]; [@B9]; [@B32]; [@B63]; [@B95]; [@B139]).

Synthesis of PA by acylation of glycerol-3-phosphate is the initiating event in phospholipid biosynthesis in both prokaryotic and eukaryotic organisms. The next step is the conversion of PA into CDP-DAG, the central liponucleotide intermediate for phospholipid biosynthesis. In bacteria, CDP-DAG is the precursor for the biosynthesis of all the major phospholipids including PG, CL, PS, and PE (produced through decarboxylation of PS) ([@B90]). In eukaryotes, PA is a precursor for both CDP-DAG and DAG; CDP-DAG is used to make PI, PG, and CL, while DAG is required for PC, PE, and TAG synthesis ([@B162]). In yeast, PS is produced from serine and CDP-DAG ([@B54]).

The enzyme CDS (alternative name: CTP:phosphatidate cytidylyltransferase) catalyzes the synthesis of CDP-DAG from CTP and PA. CDS and its homologs were initially identified as integral membrane proteins responsible for the CDP-DAG synthase activity in bacterial PMs and the ER membranes of eukaryotic cells ([@B62]; [@B147]; [@B72]; [@B142]). In 1992, a study using rat liver discovered that mitochondria also contain an intrinsic CDP-DAG synthase activity separate from the ER-localized CDS activity ([@B105]). GTP stimulated the CDS activity in the microsomes (mainly ER) whilst the mitochondrial activity was insensitive to GTP. Twenty-five years later, in 2013, the CDP-DAG synthase activity of yeast mitochondria was found to be due to Tam41, a peripheral membrane protein present on the mitochondrial inner membrane ([@B150]). Tam41 and CDS both catalyze the synthesis of CDP-DAG using PA and CTP as substrates, but share no sequence or structural homology ([@B86]; [@B68]). CDS is an integral membrane protein, whilst Tam41 is a peripheral membrane protein that binds to the membrane through its C-terminal domain ([@B86]; [@B68]).

In this review, we focus on the two unrelated families of enzymes that possess CDS activity, CDS/Cds and TAMM41/Tam41. In mammalian cells, PI synthesis is confined to the ER whilst PG and CL synthesis is restricted to the mitochondria. During PLC signaling, the rapid consumption of PI(4,5)P~2~ requires its replenishment and for this PI resynthesis is essential. The role of CDS enzymes in this process is discussed. We review recent evidence that suggest that CDS enzymes are regulated, and regulation is dependent on context. We examine how disruption of CDS enzymes can lead to metabolic disturbances, particularly, the formation of super-sized lipid droplets. CDS enzymes are expressed in protozoa and we discuss their spatial segregation from other enzymes required for PI and CL synthesis in other organelles. Finally, we suggest that the CDS family of enzymes may also contribute to CL synthesis in addition to TAMM41 requiring transfer of CDP-DAG from the ER membrane to mitochondrial membranes.

Identification of Prokaryotic and Eukaryotic Cds Enzymes {#S2}
========================================================

The gene encoding for *Cds* was first cloned in *Escherichia coli* and codes for a 27 kDa protein, predicted to contain transmembrane regions ([@B62]). The protein was purified and analysis of the acyl chain preference for PA indicated that the enzyme displays a striking preference for PAs bearing at least one double bond in their acyl moieties ([@B147]). The first eukaryotic *Cds* was cloned from *Drosophila.* This gene encodes a polypeptide of 447 amino acids with a molecular weight of 49 kDa ([@B158]). *Drosophila* Cds shares a 31% amino acid identity with bacterial Cds. Subsequently, the Cds cDNA was cloned from the yeast, *Saccharomyces cerevisiae*; the cDNA encodes a protein of 457 amino acids with a molecular mass of 52 kDa and shares 37% identity and 60% similarity with the *Drosophila* enzyme ([@B143]). Importantly, these two eukaryotic enzymes possess a hydrophilic N-terminus, which is absent in the *E. coli* Cds enzyme ([Figure 2A](#F2){ref-type="fig"}).

![Domain structures of CDS enzymes and of Tam41. **(A)** Domain structures of the CDS enzymes based upon the bacterial enzyme *Tm*CdsA from *T. maritama*. These include the N-terminal domain (blue), the Middle domain involved in dimerization (green) and the highly conserved catalytic C-terminal domain (red). Within the C-terminal domain lies the α and β loops, the CDS motif, and residues involved in coordination of metal ions crucial for catalysis. Phosphorylation sites of *Hs*CDS1/2 are also included. **(B)** Domain structures of TAMM41 enzymes based upon the yeast enzyme *Sp*Tam41 from *S. pombe*: these include the mitochondrial import sequence (purple), the NTase domain (orange) and winged helix domain (blue) (which form the catalytic binding pocket), and the C-terminal membrane binding domain (yellow).](fcell-08-00063-g002){#F2}

Cloning of CDS cDNA from human ([@B53]; [@B93]; [@B156]; [@B47]), mouse ([@B155]; [@B65]), rat ([@B133]), and pig ([@B100]) soon followed and two *CDS* genes encoding for CDS1 and CDS2 were identified. It is thought that they arose during a gene duplication event 500--900 million years ago. Thus, insects contain a single copy whilst fish and mammals possess two copies ([@B92]). Not surprisingly, all eukaryotic genomes, sequenced to date, contain Cds homologs ([@B92]). The number of *Cds* genes varies in different organisms. For example, *C. elegans* has one *Cds* gene, *Arabidopsis thaliana* genome has 5 *Cds* genes, whilst zebrafish has 2 genes. Analysis of *Cds* genes in the protozoan parasite *Toxoplasma gondii* revealed the presence of two phylogenetically divergent CDS enzymes, a eukaryotic and a prokaryotic type ([Table 1](#T1){ref-type="table"}). The CDS sequences fall into two discrete eukaryotic and prokaryotic clades ([@B77]) with the CDS signature motif (KDX~5~PGHGGX~2~DRXD; X being any amino acid) found in both clades. The CDS signature motif is present at the C-terminal region of the protein ([Figure 2A](#F2){ref-type="fig"}). The prokaryotic-type sequences are found in bacteria, cyanobacteria, red algae and selected protozoa (e.g., *Leishmania major*, *Eimeria falciformis*, and *Trypanosoma cruzi*) but not others (e.g., *Cryptosporidium parvum*, *Plasmodium falciparum*, and *Trypanosoma brucei*) ([Table 1](#T1){ref-type="table"}; [@B77]).

###### 

CDS enzymes in different organisms.

  Species                                       Prokaryote-type CDS   Eukaryote-type CDS             Tamm41   References
  --------------------------------------------- --------------------- ------------------------------ -------- --------------------------
  Human, Mice, rat, pig, zebrafish              None                  CDS1 and CDS2                  TAMM41   [@B72]; [@B14]
  *S. cerevisiae* and *S. pombe* (yeast)        None                  CdsA                           Tam41    [@B150]
  *D. melanogaster* (Flies)                     None                  CdsA                           Tam41    [@B158]
  *A. thaliana* (plant)                         *At*Cds4, *At*Cds5    *At*Cds1, *At*Cds2, *At*Cds3   Tam41    [@B166]; [@B77]
  *T. cruzi* (Kinetoplastid)                    *Tc*Cds2              *Tc*Cds1                       None     [@B77]
  *T. brucei* (Kinetoplastid)                   None                  *Tb*Cds                        None     [@B84]
  *E. falciformis* (Apicocomplexan)             *Ef*Cds2              *Ef*Cds1                       None     [@B77]
  *T. gondii* (Apicocomplexan)                  *Tg*Cds2              *Tg*Cds1                       None     [@B77]
  *P. falciparum* (Apicocomplexan)              None                  *Pf*Cds                        None     [@B77]
  *E. coli* (Bacteria)                          *Ec*CdsA, *Ec*YnbB,   None                           None     [@B62]; [@B137]; [@B138]
  *Synechocystis* sp. PCC6803 (cyanobacteria)   *Ss*Cds               None                           None     [@B136]

The structure of the bacterial *Thermotoga maritima* Cds enzyme, *Tm*CdsA, informs us that it is a dimer. Each of the *Tm*CdsA monomers contain nine transmembrane helices arranged in a novel fold containing three domains; the N-terminal domain containing a single helix (colored blue), the middle dimerization domain containing 4 helices (colored green), and the C-terminal domain comprising of four helices that contains the catalytic site (colored red) ([@B86]; [Figures 2A](#F2){ref-type="fig"}, [3A](#F3){ref-type="fig"}). Within each monomer, a funnel-shaped cavity forms penetrating halfway into the membrane. This cavity is shaped by amino acid residues from the C-terminal domain and the N-terminal domain. The cavity has dual openings allowing the simultaneous acceptance of the hydrophilic CTP and the hydrophobic PA substrate. At the bottom of the cavity, a dyad forms between ^219^Asp and ^249^Asp that coordinates a magnesium-potassium hetero-di-metal center. The position of the asparagine residues is shown in [Figure 2A](#F2){ref-type="fig"} as yellow circles. Only ^249^Asp residue is conserved in all CDS sequences. ^219^Asp is only conserved in prokaryotes and is replaced by a glycine residue ([Figure 2A](#F2){ref-type="fig"}; gray circles) in eukaryotes that presumably also coordinates the Mg^2+^. The dyad is key to the catalysis of CDP-DAG formation. The implied mechanism of this reaction is that the Mg^2+^ ion activates the phosphate head group of PA, permitting nucleophilic attack on the α-phosphate of CTP. Simultaneously, the K^+^ ion binds the remaining β and γ phosphates of the CTP, and facilitates release of the products, CDP-DAG, and pyrophosphate from the active site. Two conserved cytoplasmic loops, α and β, surround the active site and contribute to substrate binding ([Figure 2A](#F2){ref-type="fig"}).

![Cartoon structures of *Tm*CdsA and *Sp*Tam41. **(A)** CDS is an integral membrane protein and is present as a dimer and accepts the two substrates, CTP, and PA. On the cytoplasmic side of each *Tm*CdsA monomer, a funnel-shaped cavity indents half way into the membrane region. The cavity has two wide openings, which enable it to receive dual substrates, CTP from the cytoplasm and PA from the lipid bilayer at the same time. The conversion of CTP and PA into CDP-DAG and pyrophosphate occurs through a process involving the transfer of CMP group from CTP onto the phosphate group of PA. Adapted from [@B86]. Color coding is the same as *Tm*CdsA in [Figure 2](#F2){ref-type="fig"}. **(B)** The full length *Sp*Tam41 exists as a monomer and is associated to the matrix side of the inner mitochondrial membrane by the membrane binding domain at the C-terminal region (colored yellow). CTP and PA sequentially bind to the active site of Tam41. The enzymatic conversion of CTP and PA into CDP-DAG and pyrophosphate occurs through a process involving the transfer of CMP group from CTP onto the phosphate group of PA. Adapted from [@B68]. Color coding is the same as *Sp*Tam41 in [Figure 2](#F2){ref-type="fig"}.](fcell-08-00063-g003){#F3}

The three domains of life are Archaea, Bacteria and Eukaryota and they differ in their phospholipids. Whilst phospholipids of bacteria and eukaryotes consist of linear acyl chains ester-linked or ether-linked to glycerol-3-phosphate, archaeal phospholipids consist of isoprenoid chains ether-bonded to glycerol-1-phosphate ([@B89]). Nonetheless, the key step in phospholipid synthesis is the same in all three domains of life: the transfer of CMP from CTP to a glycerol-phosphate backbone catalyzed by transmembrane enzymes. CDS uses PA whilst the CDP-archaeol synthase (CarS) uses DGGGP to make CDP-archeol ([@B67]). The structure of the CarS of *Aeropyrum pernix* (*Ap*CarS) comprises of five transmembrane helices and cytoplasmic loops which form a large charged cavity for CTP and the lipophilic substrate, DGGGP to bind ([@B129]). Part of the cavity is formed by two cytoplasmic loops, also contributing to substrate binding similar to *Tm*CdsA ([Figure 2A](#F2){ref-type="fig"}). Unlike, the bacterial enzyme, *Ap*CarS lacks the dimerization domain. Nonetheless, *Ap*CarS is a structural homolog of *Tm*CdsA, although the two proteins only share 12% sequence identity. Thus, bacterial and archaeal transmembrane CTP transferases have likely evolved from a common ancestral enzyme.

Mammalian CDS1 and CDS2 {#S3}
=======================

In humans, the genes for *Cds1* and *Cds2* are located on chromosome 4q21 and 20p13, respectively ([@B47], [@B48]). The protein sequences of CDS1 and CDS2 show 72% identity and 92% similarity and the major difference is found at the N-terminal region ([@B47]; [@B65]), where the phosphorylation sites are also found ([Figure 2A](#F2){ref-type="fig"}). Human CDS1 is 461 amino acids long whereas CDS2 is slightly shorter at 445 amino acids due to a shorter N-terminal region prior to the first transmembrane domain. The mammalian CDS1 and CDS2 are integral membrane proteins which can form homodimers ([@B14]). Likewise, the bacterial CDS enzyme, *Tm*CdsA, from *T. maritama* is also a dimer ([Figure 3A](#F3){ref-type="fig"}; [@B86]). The purification of the Cds enzyme from yeast also identified a homodimer of two identical 56 kDa subunits ([@B72]; [@B20]). Furthermore, it is notable that in the BioGRID database^[1](#footnote1){ref-type="fn"}^, CDS1, and CDS2 interact with each other, suggesting that heterodimers may be possible. CDS enzymes are phosphorylated enzymes but whether this modification has any effect on enzyme activity remains to be studied. Using high throughput analysis, CDS1 was found to be phosphorylated at Ser37, conserved between human, mouse, and rat. CDS1 is also ubiquitylated at Lys270, which is also conserved across species. In human CDS2, Ser21 and Ser33 are phosphorylated whilst Lys253 and Lys328 are ubiquitylated ([Figure 2A](#F2){ref-type="fig"}). Again, these modifications are conserved in both mice and rats (data mined from <https://www.phosphosite.org>).

The ER is a continuous membrane system comprising of the nuclear envelope, flat sheets at the central perinuclear region and a network of highly curved tubules at the periphery. The subcellular localization of mammalian CDS1 and CDS2 enzymes has been mainly studied by over-expression of tagged proteins in several different cell types including COS-7 and CHO-1 cells, and the consensus is that both enzymes localize to the ER membranes ([@B133]; [@B65]; [@B74]; [@B31]). In COS-7 cells, both CDS1 and CDS2 are found at the nuclear envelope and the peripheral ER tubules. In contrast to CDS enzymes, PI synthase (PIS) localizes to the central perinuclear ER and peripheral ER tubules as well as at uncharacterized mobile structures in COS-7 cells ([@B74]). A recent study has identified that Cds1 is also at the inner nuclear membrane in yeast and contributes to lipid droplet formation in the nucleus ([@B132]).

PI is highly enriched in C18:0 at the *sn-*1 position and C20:4 at the *sn-*2 position, and this enrichment could be due to the acyl chain specificity of PA utilized by CDS enzymes. Analysis of CDS1 and CDS2 using PA with different acyl chain compositions in a detergent/phospholipid/mixed micelle-based assay indicate that the two human isoforms show different acyl chain specificities. CDS2 is selective for the acyl chains at the *sn-*1 and *sn-*2 positions, the most preferred species being *sn-*1-stearoyl, *sn-2*-arachidonoyl PA (C18:0/20:4-PA). In contrast, CDS1 showed no particular substrate selectivity, displaying similar activities for almost all substrates tested ([@B31]). However, in a different study, rat CDS1 showed the highest *in vitro* activity when C18:0/C20:4-PA was used as substrate with almost no activity detected toward PA containing saturated fatty acyl groups in both of the *sn*-1 and *sn*-2 positions ([@B133]). Although, rat CDS1 was found to prefer C18:0/C20:4-PA as a substrate, both PA from egg yolk lecithin and di-C18:1-PA gave reasonable activity ([@B133]). As these assays are done *in vitro* in the presence of detergent, the selectivity for PA species remains an open question. The important point to emphasize is that CDS1 is non-selective for the PA species and will equally utilize C18:0/20:4-PA as substrate. Additional work with purified enzymes and *in vitro* assays without detergent are required to clarify this question. It is notable that PIS that converts CDP-DAG to PI appears to show no selectivity for the acyl chain composition ([@B30]). The identification of PI remodeling enzymes suggests that a major route to the enrichment of PI with C18:0 and C20:4 probably occurs subsequent to its synthesis ([@B11]; [@B13]).

Functional Analysis of CDS Enzymes During Phospholipase C Activation {#S4}
====================================================================

The formation of CDP-DAG is the rate limiting step in the synthesis of PI. When PLC is activated for prolonged periods, as much at 30--40% of the total cellular PI is depleted ([@B15]), and therefore the extent of CDS activity would determine the rate of PI resynthesis. Studies in two model organisms, *Drosophila* and zebrafish, suggest that CDS activity controls both the availability and the extent of PI(4,5)P~2~-dependent signaling. Mutation of the single *Cds* gene in *Drosophila* leads to light-induced irreversible loss of phototransduction and retinal degeneration ([@B149]; [@B33]; [@B165]). In zebrafish, CDS-dependent phosphoinositide availability limits VEGFA signaling ([@B9]).

The importance of CDS enzymes comes from the need for the cells to maintain their phosphoinositide levels, in particular, PI(4,5)P~2~. PI(4,5)P~2~ is a substrate for PLC and for PI3K. Both enzymes are activated when agonists, hormones and neurotransmitters interact with their cell surface receptor. Activation of PI3K converts PI(4,5)P~2~ to PI(3,4,5)P~3~; although the amount of PI(3,4,5)P~3~ produced is very small compared to the resting pool of PI(4,5)P~2~, PI3K signaling is disturbed when PI(4,5)P~2~ resynthesis is disrupted as discussed below.

The PI(4,5)P~2~ cycle starts with the hydrolysis of PI(4,5)P~2~ by PLC at the PM ([Figure 4](#F4){ref-type="fig"}). This forms the second messengers inositol triphosphate \[I(1,4,5)P~3~\] and DAG. The soluble I(1,4,5)P~3~ causes the release of intracellular calcium ions from the ER lumen; I(1,4,5)P~3~ gets dephosphorylated to inositol where it is re-used for PI synthesis. The membrane-bound DAG activates PKC; DAG is removed by phosphorylation to PA by DAG kinases (DAGK). The newly formed PA is transported to the ER by Class IIa PI/PA transfer proteins (PITPNM1/2 (alt. name Nir2/3)) ([@B41]; [@B24]). At the ER, PA is converted into CDP-DAG by CDS enzymes, the rate-limiting step in the synthesis of PI ([@B94]; [@B114]) and in the PI(4,5)P~2~ cycle, CDP-DAG is then converted into PI by PIS. Once PI is formed, either Class I PI/PC transfer proteins (PITPα/β) or Class IIa PITPNM proteins can transport it to the PM where it undergoes two sequential phosphorylations by resident lipid kinases to regenerate PI(4,5)P~2~. This completes the PI(4,5)P~2~ cycle ([Figure 4](#F4){ref-type="fig"}).

![The PI(4,5)P~2~ cycle. The PI(4,5)P~2~ cycle begins with the hydrolysis of PI(4,5)P~2~ and formation of the second messengers, I(1,4,5)P~3~ and DAG. I(1,4,5)P~3~ causes an increase in intracellular calcium concentration before being dephosphorylated into inositol. DAG is phosphorylated to PA at the plasma membrane (PM) by DAG kinase (DAGK) and transferred to the ER via Class IIa PITPs (PI/PA transfer proteins) PITPNM1/2. At the ER, PA, and CTP are converted to CDP-DAG by CDS enzymes (CDS1 and CDS2). CDP-DAG is synthesized into PI and this is catalyzed by the enzyme PI synthase (PIS). PI is transferred to the PM by Class I PITPs (PI/PC transfer proteins) PITPα/β and Class IIa PITPNM1/2, for phosphorylation to PI(4,5)P~2~ by the resident enzymes, PI4KIIIα and PIP5K. PITPNM1/2 are also known as Nir2/Nir3.](fcell-08-00063-g004){#F4}

During PLC signaling, the PA formed at the PM will be enriched with stearic acid (C18:0) and arachidonic acid (C20:4) reflecting the PI(4,5)P~2~ composition ([@B16]; [@B13]). Similarly, when PLD hydrolyzes PC, which usually occurs concurrently with PLC activation, the resultant PA reflects the fatty acid composition of PC ([@B123]). The *sn-*1 position of PC is mainly C16:0 and C18:0 and the *sn-*2 position is mainly C18:1 and C18:2. Whether these different PA species are kept metabolically separate at the PM is not known. Since the PI(4,5)P~2~ cycle occurs at membrane contact sites, the intermediates of the cycle may remain compartmentalized ([@B24]). It has been generally assumed that the PA produced due to PLC activation remains in the PI(4,5)P~2~ cycle and is re-used for PI resynthesis thus maintaining the fatty acid composition ([@B102]; [@B18]). However, in a study of the PI acyl chain composition of platelets, the fatty acid profile of PI had changed after stimulation with thrombin. The enrichment of C18:0/C20:4 was no longer apparent, implying newly formed PI, made through *de novo* synthesis, lacked any specificity to create the typical profile of PI ([@B124]).

To maintain the C18:0/C20:4 of PI during the PLC-PI(4,5)P~2~, other enzymes in the cycle such as DAGK would also need to show selectivity. There are 10 mammalian DAGK subdivided into five types and are differentially expressed. DAGKε is the only enzyme that shows selectivity for C18:0/C20:4-DAG *in vitro* and has been suggested as the DAGK responsible for metabolizing PLC-derived DAG ([@B91]; [@B145]; [@B35]; [@B134]). The enzyme localizes to the ER raising the question of its role in phosphorylating DAG at the PM during the PI(4,5)P~2~ cycle ([@B115]). EM immuno-tomography has shown that DAGKε localizes at ER-PM membrane contact sites in Purkinje cells in the brain ([@B61]). Thus, it is suggested that DAGKε can access DAG from the PM and deliver it to the ER ([@B16]). However, the enzyme is not ubiquitously expressed indicating that depending on cell-type, different DAGKs could be more relevant. Another DAGKα, an isoform enriched in T lymphocytes, is cytosolic and translocates to the PM upon stimulation suggesting that this DAGK could be responsible for DAG phosphorylation in some cells including T cells ([@B135]; [@B101]). It is non-specific for the substrate meaning that C18:0/C20:4-DAG could be utilized as well ([@B101]).

The PI(4,5)P~2~ cycle is not a closed cycle. The intermediates of the PI(4,5)P~2~ cycle such as DAG and PI can exit the cycle and are not necessarily recycled back to produce more PI(4,5)P~2~ ([@B131]). Both DAG and PI can be metabolized and exit the PI(4,5)P~2~ cycle; DAG is degraded by DAG lipase to the endocannabinoid, 2-arachidonoylglycerol (2-AG) and PI to *sn*-2-arachidonoyl lyso-PI by the phospholipase A1, DDHD1 ([@B66]). Both are bioactive metabolites acting as agonists on cell surface receptors ([@B4]; [@B8]). Thus newly synthesized PI has to enter the PI(4,5)P~2~ cycle to maintain phosphoinositide levels. The question of how *de novo*-synthesized PI becomes enriched with its characteristic fatty acid composition is likely through the remodeling of PI by phospholipase A and PI acyl transferases ([@B11]; [@B17]; [@B13]). As per the other phospholipids, PI has its own set of acyl transferases, LPIAT1 (also known as MBOAT7) and LYCAT (also known as AGPAT8), which allow a cycle of deacylation-reacylation to take place, enriching PI with specific acyl chains. LYCAT adds stearic acid (C18:0) to the *sn*-1 position and LPIAT1 adds arachidonic acid (C20:4) to the *sn*-2 position.

Studies in *Drosophila*, zebrafish and cultured mammalian cell-lines all highlight the importance of CDS enzymes in phosphoinositide signaling. All these studies suggest that CDS activity controls the extent of PI(4,5)P~2~-dependent signaling. Vertebrates have two CDS genes, *Cds1* and *Cds2*, and the protein products of both genes localize to the ER ([@B31]). Of the two CDS enzymes, is there a separation of function for *de novo* synthesis of PI versus resynthesis of PI during PLC signaling? CDS1 has a restricted level of expression whilst CDS2 expression is ubiquitous ([@B133]; [@B155]; [@B65]). As described later, *Cds* genes can also be induced when high rates of PI synthesis are required ([@B15]).

Studies from *Drosophila* highlight the importance of CDS in the visual phototransduction system. The underlying phototransduction machinery in photoreceptor neurons is rhodopsin-based Gαq-protein-coupled signaling cascade where light activates PLCβ, encoded by the *norpA* gene. Disruption of the *Cds* gene in photoreceptor cells limits PI(4,5)P~2~ availability and therefore PLC-mediated signaling leading to a decreased amplitude of the light response ([@B158]; [@B50]; [@B85]). In the fly there is a single *Cds* gene but with two transcripts ([@B158]). Loss of the *Cds* gene is lethal. Mutations in the eye-specific *Cds* gene results in a defect in phototransduction and retinal degeneration. Light activation results in PI(4,5)P~2~ hydrolysis that cannot be replenished in the *eye-Cds* mutants. Thus, *Cds* mutants cannot sustain a light-activated current. Interestingly, the Cds enzyme was rate-limiting as transgenic animals that over-expressed the enzyme 4--5 fold display a large and significant increase in the amplitude of the light response when compared to wild-type animals ([@B158]).

In zebrafish, vascular growth is dependent on VEGFA-stimulated PLC signaling and is reliant on CDS enzymes for PI(4,5)P~2~ availability ([@B119]). Like other vertebrates, zebrafish also have two CDS genes, *Cds1* and *Cds2* but only *Cds2* mutants result in vascular-specific defects *in vivo.* Vascular growth is mainly governed by angiogenesis where new blood vessels are formed from existing vessels, whilst vasculogenesis is the *de novo* formation of blood vessels using stem cells. In addition, vessel regression also plays important roles in embryonic development and tissue homeostasis. VEGFA, acting through the tyrosine kinase receptor, VEGF receptor 2 on endothelial cells, governs vasculogenesis, angiogenesis and regression and acts through the activation of both PLCγ and PI3K. Both use PI(4,5)P~2~ as their substrates. PI3K catalyzes the conversion of PI(4,5)P~2~ to PI(3,4,5)P~3~ and PLCγ hydrolyzes PI(4,5)P~2~. Using the zebrafish model system, mutations in *Cds2* resulted in vascular-specific defects *in vivo* and failure of VEGFA-induced angiogenesis *in vitro* ([@B119]; [@B55]). Interestingly, morpholinos that targeted CDS1 also caused a mild vascular phenotype and morpholinos that targeted both CDS1 and CDS2 resulted in early embryonic lethality. The CDS2 deficient phenotypes could be rescued by artificial elevation of PI(4,5)P~2~ and increased CDS2 levels promoted excess angiogenesis ([@B119]). As expected, CDS2 is enriched in the endothelium ([@B119]).

In addition to vascular defects, in zebrafish, CDS2 mutants switched the output of VEGFA signaling from promoting angiogenesis to inducing vessel regression ([@B165]). It was suggested that without the CDS2-controlled PI(4,5)P~2~ resynthesis, the VEGFA-PLCγ signaling axis hydrolyzes PI(4,5)P~2~ leading to depletion of PI(4,5)P~2~ and thus inhibition of PI3K-catalyzed PI(3,4,5)P~3~ formation. FOXO1 accumulation in the nucleus can thus trigger reverse migration of angiogenic endothelium. Live cell imaging of zebrafish revealed the reverse migration of the angiogenic endothelium in the CDS2 mutant upon VEGFA stimulation.

The observations made in zebrafish were also made in mice. *CDS2* was deleted specifically in the adult endothelium in mice and endothelial regression was observed in the postnatal retina. Furthermore, in tumor models, endothelial CDS2 deficiency induced vessel regression, and suppressing tumor growth. Stimulation by VEGFA reduced PI(4,5)P~2~ which could not be replaced in the absence of CDS2-controlled PI synthesis. This caused a deficiency in PI(3,4,5)P~3~ permitting FOXO1 to trigger regression of CDS-null endothelium ([@B165]). These results confirm the importance of CDS2 in maintaining PI(4,5)P~2~ levels during PLC signaling. In its absence, it causes disturbances in PI(3,4,5)P~3~ as well.

In cardiac myocytes, the Gαq-protein-coupled receptor agonists such as angiotensin II, vasopressin, endothelin-1, and phenylephrine activate PLC. Cardiac myocytes respond to physiological and pathological stimuli by increasing their size (hypertrophy) and Gαq-phosphoinositide signaling system is responsible for the development of pathological hypertrophy ([@B6]; [@B149]; [@B116]; [@B96]). Sustained vasopressin signaling in a H9c2 cardiac cell line over a 24 h period recapitulates the hypertrophic response and this is coupled to continuous PLC signaling ([@B15]). PI levels are depleted by 50% under these conditions, and the cells respond by upregulating the expression of CDS1. CDS2 expression is unaffected. The increase in CDS1 mRNA was dependent on PKC activation of cFos expression ([@B15]). Other studies using cardiomyocytes have reported that other agonists such as norepinephrine also stimulate cFos expression due to PLC activity via PKC likely increasing CDS1 expression as well ([@B146]).

Interestingly, cFos is not only a regulator of CDS1 mRNA expression, it can also directly bind to CDS1 at the ER and activate it ([@B3]; [@B19]). The N-terminal domain of cFos interacts with CDS1 resulting in the increase in CDS1 activity *in vitro* and also in tumor cells. Growth of tumor cells require high rates of lipid synthesis to support membrane biogenesis, and two transcription factors of the AP-1 family that activate phospholipid synthesis are Fra-1 and cFos. In breast tumors, both transcription factors are also expressed in the cytoplasm as well as the nucleus ([@B108]). For cFos and Fra-1 to promote activation of phospholipid synthesis, it associates with CDS1 in the ER through the cFos N-terminal domain (1--38 a.a.). The increase in the catalytic activity of CDS1 is through the basic domain (a.a. 139--159) of cFos. Using FRET analysis, the N-terminus of Fra-1 and cFos was shown to physically associate with CDS1 in cells. Interestingly, expression of the N-terminus of either cFos or Fra-1 resulted in a decrease in the proportion of full-length Fra-1 or cFos at the ER compartment. Expression of the N-terminal domain of Fra-1 or cFos in MDA-MB231 or 4T1 cells results in inhibition of cell growth, both in tissue culture and when examined in a Balb/c mice tumor model. When the tumor was excised from the mice, and the CDS activity monitored, an increase was observed that could be reversed upon stripping the tumor samples with IM KCl to remove the Fra-1 and cFos from the membranes ([@B126]).

To summarize, there is now substantial evidence that PI synthesis following PLC activation is dependent on CDS enzymes. In the case of the zebrafish, CDS2 appears to be more important than CDS1, whilst in the cardiomyoblast cell line H9c2, CDS1 appears to be more important. Importantly, the level of CDS expression appears to regulate the extent of signaling.

CDS Enzymes Determine Size of Lipid Droplets {#S5}
============================================

Phosphatidic acid is a substrate for CDS enzymes, as well as a substrate for lipins. Thus, PA can be channeled to make CDP-DAG or used to make DAG. DAG can then be routed to either TAG or to the synthesis of PC and PE. Inhibition of CDS enzymes would result in an increase in PA, which could be redirected to generate DAG by lipins. DAG could then be channeled to TAG or to PC and PE synthesis. Loss-of-function CDS mutants have been identified in both budding and fission yeast, *Drosophila* and in cultured mammalian cells and in all cases, results in the formation of super-sized lipid droplets (LDs) ([@B36]; [@B52]; [@B88]; [@B125]).

Lipid droplets are highly dynamic organelles that originate from the ER before they expand and mature. Super-sized LDs can form either by expansion or by coalescence of contacting LDs. Studies in both budding and fission yeast show that loss of function mutations in *Cds1* lead to enlarged lipid droplets. However, the mechanism appears to be different. In the budding yeast *S. cerevisiae*, PA has been identified as one of the regulators of LD growth. In a genome-wide screen, ten yeast mutants producing super-sized LDs were isolated. The mutated genes included *Cds1*, and biochemical and genetic analyses revealed that a common feature of the mutants was an increase in PA. PA was found to facilitate the coalescence of contacting LDs, resulting in the formation of super-sized LDs ([@B36]; [@B125]). In contrast, in the fission yeast, *S. pombe*, no increase in PA was observed but an increase in DAG and TAG was found, suggesting that cellular PA was shunted toward TAG biosynthesis. The LDs were in close proximity to the ER and it was suggested that growth of the LDs was by expansion ascribed to the presence to TAG synthases on the LDs ([@B52]).

In cultured HeLa cells (human) and 3T3-L1 preadipocytes (murine), downregulation of either CDS1 or CDS2 by RNAi resulted in super-sized LDs but only in the presence of exogenously added oleic acid (C18:1) ([@B125]; [@B159]). Addition of oleic acid to untreated cells led to an increase in TAG levels and this was marginally increased in CDS2 siRNA-treated cells. The formation of super-sized LDs appears to be dependent on the modulation of PA levels at the ER and on the lipid droplets, similar to that seen in *S. cerevisiae* ([@B159]). Knockdown of Lipin1 also resulted in super-sized LDs and this could be reversed by over-expression of either CDS1 or CDS2. Importantly, knockdown of Lipin1 did not increase TAG levels but only increased PA levels, confirming that the increase in PA was likely responsible for the super-sized lipid droplets. Overexpression of CDS1 or CDS2 decreased PA levels and inhibited lipid droplet expansion. Thus, this data supports the model that the super-sized LD phenotype is partly due to changes in PA and not just due to increased TAG synthesis.

Although knockdown of either CDS1 or CDS2 resulted in super-sized lipid droplets, the mechanisms appear to be different ([@B159]). LD size in CDS1-deficient cells could be restored by downregulating Fsp27/CIDEC (cell death-inducing DFF45-like effector C). CIDEC is a LD-associated protein that promotes lipid droplet growth by TAG transfer from smaller to larger LDs ([@B45]); in CDS1-knockout cells, CIDEC levels were increased significantly. Conversely, knockdown of CIDEC restored LD size to normal levels in the CDS1-knockout cells. This confirmed that super-sized LD formation in CDS1-deficient cells results from enhanced LD fusion/lipid transfer mediated by CIDEC proteins ([@B12]). On the other hand, reducing expression of DGAT2 and GPAT4 rescued the enlarged LD-phenotype in CDS2-deficient cells. CDS2 deficiency promoted the LD association of DGAT2 and GPAT4. GPAT4 produces PA whilst DGAT2 consumes PA to make TAG. Thus, increased TAG synthesis could be responsible for super-sized LD formation.

Besides a potential role of PA in LD expansion, PA is also implicated in the differentiation of adipocytes. PA accumulation in the ER membrane upon CDS1/CDS2 depletion is thought to inhibit adipocyte differentiation by possibly interfering with PPARγ function required for the differentiation process. Depletion of CDS1 by siRNA resulted in inhibition of adipocyte differentiation, whereas depletion of CDS2 had a moderate inhibitory effect. It is notable that knockdown of CDS2 results in an increase in CDS1 mRNA ([@B125]).

Down-Regulation of CDS Enzymes Causes Disturbances in PI Levels {#S6}
===============================================================

In HeLa cells, knockdown of CDS1 or CDS2 decreased PI levels, whilst knockdown of CDS2 also led to a decrease in PG ([@B125]). The decrease in PI levels was not dependent on the presence of oleic acid, unlike the super-sized lipid droplets. In H9c2 cells, a decrease in all phosphoinositides was observed: the decrease was approximately 30% for PI, PIP and PIP~2~ in either CDS1 or CDS2 knockdown cells. No effects of CDS1 or CDS2 knockdown on CL was observed further supporting the findings that TAMM41 is responsible for CL synthesis.

Phosphoinositides have important functions in cells including maintaining the cytoskeletal network. Upon knockdown of CDS1 and CDS2 by siRNA, H9c2 cell morphology was drastically altered ([@B15]). Although the knockdown of CDS1 and CDS2 led to similar decreases in phosphoinositide levels, there were subtle differences in the morphological changes. The stress fibers usually seen in the H9c2 cells had lost form and become wispy; the F-actin strands were depolymerized, and a lot of the actin had begun to pool around the edges of the cells. This was much more pronounced in the CDS-knockdown cells. The knockdown cells were significantly smaller than the untreated cells, with CDS2 siRNA-treated cells being much more affected. This phenotype is similar to that observed in *Drosophila* salivary glands discussed below ([@B88]). Also, the mitochondria and the trans golgi network (TGN) became fragmented. These drastic changes observed clearly indicate that disruption in the levels of phosphoinositides has a pleiotropic impact on the cells.

Functional Studies of CdsA Requirement in Different Tissues in *Drosophila* {#S7}
===========================================================================

Several studies undertaken in *Drosophila* have examined *CdsA* function in specific tissues at different stages of development and in adult flies. This provides a snapshot of how an enzyme participates in functional responses in the context of the specific cellular proteome. Tissue-specific phenotypes are observed when the *CdsA* gene is disrupted in particular tissues. Deletion of the *CdsA* gene in the whole organism is lethal but the use of RNAi knockdown in specific cell types and tissues has provided a wealth of information about the specific impact of *CdsA*. *Drosophila* have a single *CdsA* gene, which has two transcripts. As the sole *Drosophila* CDS, *CdsA* is essential for embryogenesis ([@B88]), phototransduction ([@B158]), metamorphosis ([@B87]), and spermatogenesis ([@B81]). Loss of *CdsA* perturbs lipid composition, including increased levels of PA coupled with the reduction of PG, PI, and its derivatives. Loss of *CdsA* function causes a variety of phenotypes in different tissues, which can be attributed to the alterations of one or more of these lipids.

The requirement of eye-specific *CdsA* in PLC-dependent phototransduction has already been described above where CdsA is required for maintaining phosphoinositide levels for PLC signaling. CdsA also plays important roles during development ([@B88]). There is an increase of nearly 200-fold in body mass during the first 4 days of larval growth of *Drosophila*. Tissues including brain, salivary gland and imaginal discs do not accumulate neutral fat unlike the fat body at this stage. CdsA is widely expressed in larval tissues including salivary gland, fat body, and brain and muscle. Whole animal *CdsA RNAi*, which decreases CdsA transcripts by 40%, causes an increase in lipid accumulation due to an increase in TAG in many tissues including larval imaginal discs, brain, salivary gland, prothoracic gland, proventriculus, and hindgut. The most prominent response was in salivary glands and prothoracic gland. In addition to the fat storage phenotype, the cell size was much smaller. Analysis of the salivary gland indicated that loss of *CdsA* also resulted in a reduction in both PI(3,4,5)P~3~ and in phospho-Akt, downstream products of insulin stimulation. The total level of PI and PG were also reduced with an increase in PA. In contrast, overexpression of CdsA in the salivary gland resulted in an increase in both PI and PG. PI levels were also decreased when PIS transcripts were reduced. Similarly to *CdsA RNAi* salivary glands, *Pis RNAi* salivary glands were small and accumulated lipid droplets. In this case, the decrease in PI was accompanied by an increase in PG indicating that CDP-DAG was shunted toward PG synthesis. Thus, CdsA knockdown results in a decrease in PI and this ultimately disrupts insulin signaling which is critical for providing the growth signal. In addition, PA was diverted to make TAG resulting in ectopic lipid storage.

Interestingly, perturbation of the insulin pathway caused a reduction of CdsA transcripts ([Table 2](#T2){ref-type="table"}). In contrast, when FOXO1, a downstream target of phospho-Akt was deleted, CdsA levels increased. Thus it would appear that insulin signaling and CdsA modulate the balance of growth and lipid storage via a positive feedback loop. CdsA positively regulates the activity of the insulin pathway by provision of PI for PI(3,4,5)P~3~ production, and the insulin pathway increases the transcription of CdsA. Thus, this study conducted *in vivo* reveals the intrinsic connections between CDS, phosphoinositide metabolism and insulin signaling in coordinating cell growth and neutral lipid storage ([@B88]).

###### 

Regulation of CDS1 and CDS2 mRNA by different mechanisms.

  Condition                                                                                                Up-regulated    Down-regulated   References
  -------------------------------------------------------------------------------------------------------- --------------- ---------------- ------------
  Perturbation of the insulin pathway in *Drosophila* by Akt RNAi or by dominant-negative PI3K                             CdsA             [@B88]
  Akt over-expression or by loss of Foxo in *Drosophila*                                                   CdsA                             [@B88]
  H9c2 cells stimulated with either vasopressin (16h) or with PMA (24 h)                                   CDS1                             [@B15]
  PGC-1α/β heart-specific knockout mice                                                                                    CDS1             [@B80]
  PGC-1α or PGC-1β over-expression in neonatal rat cardiac myocytes                                        CDS1                             [@B80]
  Palmitic acid: increases p53 and SIRT6. Both form a complex and bind to the promoters of CDS1 and CDS2   CDS1 and CDS2                    [@B83]
  Loss of miR-16                                                                                                           CDS2             [@B160]
  Differentiation of 3T3-L1-preadipocytes *in vitro* for 8 days                                            CDS1                             [@B125]
  Low ZEB1/2 expression in non-small cell lung cancer (NSCLC) cell lines                                   CDS1                             [@B42]
  ZEB1/2 over-expression H358 cell line                                                                                    CDS1             [@B42]
  AMPKa2^--/--^mice: CL levels decreased by 25% in heart and the mitochondria are disorganized                             CDS2             [@B7]
  *Tamm41* knockout in zebrafish causes defects in mitophagy                                               CDS1                             [@B161]

Larvae metamorphosis to pupae after day 4 is disrupted in *CdsA RNAi* flies. Metamorphosis is dependent on the steroid hormone, ecdysone. Ecdysone is stored in the prothoracic gland and during larval to pupal transition, neuronal prothoracicotropic hormone triggers its release. Unlike the salivary gland where *CdsA RNAi* decreases the cell size, the cell size of the prothoracic gland is not reduced. Nonetheless, *CdsA RNAi* significantly reduces the level of PI(4,5)P~2~ (as well as PI), the substrate for PLC of the prothoracic gland. It is suggested that *CdsA RNAi*, by reducing the levels of PI(4,5)P~2~, subsequently leads to the reduction of PLC activation and thus I(1,4,5)P~3~/Ca^2+^; this mediates ecdysone exocytosis and thus results in the metamorphosis defect ([@B87]).

In CdsA-depleted testes, due to a hypomorphic mutation in *CdsA*, spermatogenesis is disrupted. The *CdsA* mutant shows a defect in spermatid individualization and enlargement of mitochondria and the axonemal sheath of the spermatids. A strong reduction in PI coupled with an increase in PA and TAG is observed. Although PI is decreased, this does not appear to result in a decrease in PI(4)P or PI(4,5)P~2~. Rather, the elevation of PA causes the male sterile phenotype as restoration of PA to normal levels rescues the spermatogenesis defect in *CdsA* mutants ([@B81]). Reduction in CdsA activity causes an elevation of total PA by sevenfold. How an increase in PA *per se* disrupts the complex process of spermatogenesis is not known. It is interesting to note that CdsA was previously described to function in rhabdomere biogenesis in the *Drosophila* eye, based on the analysis of the hypomorphic *Cds* allele ([@B127]). In adult fly photoreceptors, *CdsA* mutant exhibits elevated levels of PA and depletion of PI(4,5)P~2~, which disrupts rhabdomere biogenesis and causes severe light-dependent photoreceptor degeneration ([@B158]; [@B127]). Elevation of a single PA species (C34:2-PA) disrupted membrane transport to the apical domain in *Drosophila* photoreceptors and caused defective rhabdomere biogenesis in *CdsA* hypomorphic mutants ([@B127]).

In summary, the studies in the different tissues of *Drosophila* reveal that disruption of *CdsA* (by either *CdsA RNAi* or by hypomorphic *CdsA* mutants) has a pleiotropic effect. Some of the phenotypes are attributed to increases in PA, others are due to defects in PLC and in PI3K signaling due to loss of PI levels, and the lipid storage phenotype is likely due to increases in TAG.

Regulation of CDS1 and CDS2 Expression by Multiple Mechanisms {#S8}
=============================================================

Recent studies indicate that both CDS1 and CDS2 expression levels are regulated and multiple mechanisms have been identified ([Table 2](#T2){ref-type="table"}). A recent study reported that treatment of several cell lines including HCT116, LoVo, and HepG cells with palmitic acid led to an increase in both CDS1 and CDS2 mRNA ([@B83]). Palmitic acid also caused an increase in p53 and in SIRT6, a histone deacetylase. Knockdown of either p53 or SIRT6 abolished the increase in CDS1 and CDS2 mRNA leading to the conclusion that the increase in mRNA levels required both p53 and SIRT6. p53 and SIRT6 have been shown to interact, and the resulting complex was found to bind to the promoter region of *CDS1* and *CDS2*. SIRT6 was found to recruit RNA polymerase II and, importantly, this recruitment was dependent on p53 ([@B83]).

Amongst its many functions, p53 regulates lipid metabolism including the acyl chain composition of PI ([@B113]). Sirtuins are the guardians of mammalian lifespan and SIRT6 protects against pathological damage caused by diet-induced obesity ([@B69]; [@B73]; [@B44]). In particular, SIRT6 is protective against accumulation of fats in the liver. In contrast, saturated fatty acids in the diet including palmitic acid induces intracellular lipid accumulation. In response to palmitic acid, the p53 and SIRT6 are induced and form a complex that binds to the promotors of CDS1 and CDS2, two enzymes required for PI synthesis ([@B83]). Thus, wild type p53 not only shifts the PI acyl chain composition from mono-unsaturated to saturated, it also increases the enzymes that make CDP-DAG, the rate limiting step in PI synthesis. It should be noted that the study by [@B83] suggested that p53 and SIRT6 cooperate to regulate CL biosynthesis despite other known genes involved in CL synthesis were unaffected by palmitic acid treatment. Thus, their underlying assumption was that CDS1 and CDS2 were required for CL synthesis, not PI synthesis. It is more likely that CDS1 and CDS2 participate in PI synthesis. A deficiency in cellular PI is thought to promote non-alcoholic fatty liver disease ([@B103]) and an increase in PI levels by induction of CDS1 and CDS2 may be protective against accumulation of fats. In this context, it is interesting to note that gain of function mutations in p53 leads to profound changes in the fatty acid profile of PI toward less saturated acyl chains ([@B113]). As described before, in many tissues and cell types, PI is highly enriched in one particular species: C18:0/C20:4.

Another regulator of CDS1 and CDS2 expression is the transcriptional coregulator, PGC-1α/β. PGC-1α/β is a member of a family of transcriptional coactivators that play key roles in the regulation of mitochondrial biogenesis and metabolism ([@B28]). Expression of CDS1 mRNA was reduced in both PGC-1α^--/--^ and PGC-1β^--/--^ mice with the greatest reduction in the double knockout. Conversely, expression of PGC-1α or -1β independently increased CDS1 mRNA in neonatal rat cardiac myocytes nearly 10-fold ([@B80]). The *Cds1* promoter region was found to possess two conserved ERR binding site sequences and combined expression of PGC-1α or PGC-1β with ERR in differentiated C2C12 myoblasts resulted in synergistic transcriptional activation of the *Cds1* gene compared to PGC-1α or β on its own. Deletion of the ERR binding sites from the promoter region completely abolished the activating effects of PGC-1α. PGC-1α expression is highly inducible at the transcriptional level in response to a variety of upstream signaling pathways including energy deprivation, Ca^2+^, NO, and cAMP ([@B121]). PGC-1αβ^--/--^ hearts from mice show a mitochondrial cristae-stacking abnormality and a decrease in CL levels ([@B80]). Thus, PGC-1α induced CDS1 expression would suggest that ER-localized CDS1 might provide CDP-DAG for CL synthesis to mitochondria.

Cds1 mRNA expression is also regulated by ZEB1, a zinc finger E-Box transcriptional repressor ([@B42]). ZEB1 drives the epithelial to mesenchymal transition (EMT) through repression of epithelial genes ([@B43]). The expression of ZEB1 and Cds1 mRNA was monitored in 22 NSCLC (non-small cell lung cancer) cell-lines and an inverse relationship was observed ([@B42]). This result was validated in H358 cells; over-expression of ZEB1 decreased CDS1 mRNA whilst knockdown of ZEB1 increased CDS1 mRNA expression. The polarity of epithelial cells is maintained by high levels of PI(4,5)P~2~ at the apical surface and of PI(3,4,5)P~3~ at the basolateral surface ([@B25]; [@B98]; [@B144]). Thus, a decrease in CDS1 mRNA during mesenchymal transition would cause a reduction in PI levels aiding in this process.

Gene expression can be silenced by microRNAs (miRNAs) that function primarily by targeting the 3′-untranslated region (3′-UTR) of specific mRNAs. miR-16 can directly recognize the 3′-UTR of CDS2 and mediate the post-transcriptional inhibition of this gene ([@B160]). miR-16 is ubiquitously expressed and its loss has been linked to many types of cancers, such as chronic lymphocytic leukemia, prostate cancer and lung cancer ([@B122]). Loss of miR-16 would increase CDS2 expression and it can be speculated that increased CDP-DAG would provide substrates to make PI(4,5)P~2~ and PI(3,4,5)P~3~ contributing toward the cancer phenotype.

AMP activated protein kinase (AMPK) controls energy homeostasis and deletion of AMPKα2, the main cardiac isoform, leads to decreases in CL levels by 25% and impairment of oxidative capacity due to defects at complex I of the respiratory chain ([@B7]). The mitochondria and myofibrils in myocytes are arranged in a regular ordered manner and the AMPKα2 knockout mice showed myofibrillar disorganization and irregular arrangement of the mitochondria. Surprisingly, the decrease in CL was accompanied by a decrease in CDS2 mRNA ([@B7]). However, CDS1 or TAMM41 were not examined leaving open the possibility that these enzymes may also be affected.

Cdp-Dag Synthase in Bacteria {#S9}
============================

In bacteria, CDP-DAG serves as a precursor of the major phospholipids including PG, CL, PS, and PE (produced through decarboxylation of PS) ([@B62]; [@B147]; [@B120]). The *E. coli* CdsA, responsible for CDP-DAG formation, comprises nine transmembrane domains with a CDS signature motif ([@B137]; [@B138]; [Figure 2A](#F2){ref-type="fig"}). *CdsA* is an essential gene, but mutants with decreased activity have been isolated that accumulate PA that leads to membrane dysfunction ([@B39]; [@B40]).

In addition to the synthesis of the main lipids, CdsA is also required for the synthesis of a glycolipid, MPIase (membrane protein integrase). In this reaction, CDP-DAG, first synthesized by CdsA, incorporates GlcNAc-1-phosphate to produce GlcNAc-PP-DAG whilst associated with the enzyme. GlcNAc-PP-DAG is the precursor of MPIase. MPIase is composed of a glycan chain and DAG connected through a pyrophosphate linker and is required for integration of membrane proteins ([@B117]; [@B138]). Thus, CdsA possesses two separate activities, the ability to make CDP-DAG and to make MPIase.

Recently, *YnbB* was identified as a *CdsA* paralog with a highly homologous C-terminal half ([Figure 2A](#F2){ref-type="fig"}), where the catalytic site resides. Under *CdsA*-depleted conditions, YnbB over-production was able to restore MPIase, but not phospholipid levels. *YnbB* complemented the growth defect of the *CdsA* knockout when Tam41, the yeast mitochondrial enzyme, was co-expressed, indicating that YnbB possess activity for MPIase synthesis but not for phospholipid synthesis. The *YnbB* knockout exhibits no defects in phospholipid or MPIase biosynthesis indicating that CdsA normally fulfils both functions. However, when *CdsA* is deleted, PA accumulation and depletion of MPIase is observed. YnbB expression restores MPIase but not phospholipid biosynthesis. Likewise, Tam41 expression suppresses PA accumulation but is unable to restore MPIase synthesis.

Whilst the C-terminal half of YnbB is homologous to that of CdsA, no significant homology is found in the N-terminal halves ([Figure 2A](#F2){ref-type="fig"}). Both CdsA and YnbB can make CDP-DAG *in vitro*. By creating chimeras of the two enzymes, it was revealed that the conserved C-terminal halves are similarly active in both phospholipid and MPIase synthesis, but that the N-terminal half of YnbB is not sufficient for phospholipid biosynthesis. In effect, the N-terminal half of CdsA is required to accelerate CDP-DAG synthesis ([@B137]).

YnbB is conserved among a wide range of bacteria strongly suggesting that it is a backup enzyme for MPIase biosynthesis, since MPIase is essential for membrane protein integration and therefore cell growth. Based on the crystal structure, *Tm*CdsA comprises three domains, namely an N-domain, M-domain and a C-domain ([Figure 2A](#F2){ref-type="fig"}). The M-domain comprises the dimer interface, and the C-domain contains the active site. In the structure, the N-domain and the C-domain come close to form a gate into the lipid bilayer for CDP-DAG. Therefore, it was suggested the N-domain participates in the release of CDP-DAG. The N-domain of CdsA and YnbB are not homologous ([Figure 2A](#F2){ref-type="fig"}) and this could contribute to the different rates of CDP-DAG biosynthesis. The eukaryotic homolog of CdsA, *Sc*CdsA or human CDS1 were able to complement *CdsA*-null bacteria provided that *Tam41* was also co-expressed. It would appear that *Sc*CdsA and human CDS1, but not Tam41, are also able to synthesize MPIase ([@B138]). The requirement of co-expression of Tam41 and the eukaryotic homolog of CdsA would suggest that the eukaryotic enzymes are less efficient in making CDP-DAG in a prokaryotic setting. An interesting point to emerge from these studies is whether MPIase is also made in eukaryotes by CDS enzymes and is required for integration of membrane proteins.

Mutations in Bacterial Cdsa Cause Resistance to the Drug, Daptomycin {#S10}
====================================================================

The anti-bacterial lipopeptide daptomycin (DAP) is used as a therapy against β-lactam-resistant *Streptococcus mitis/oralis* strains. The target of DAP is thought to be PG ([@B110]). Unlike other bacteria, *S. mitis/oralis* strains rapidly develop resistance to DAP due to loss of function mutations in *CdsA* ([@B104]). DAP-resistant strains show loss of PG and CL and an increase in PA. Like other CdsA homologs, *CdsA* of *S. mitis/oralis* is predicted to possess nine transmembrane domains with a similar topology to *Tm*CdsA, with cytosolic binding loops (α and β), and the conserved CDS motif ([Figure 2A](#F2){ref-type="fig"}). Mutation of Asp^222^ to Asn was found in the resistant mutant. Asp^222^ of *S. mitis/oralis* CdsA aligns with Asp^219^ of *Tm*CdsA, which forms part of a cation-binding Asp-Asp dyad essential for enzymatic activity.

Cdp-Dag Synthase in Plants {#S11}
==========================

In *Arabidopsis thaliana* CDS proteins are encoded by five genes, *CDS1*-*CDS5* ([@B51]). In addition, *CDS2* and *CDS4* genes are alternatively spliced resulting in potentially 10 proteins. CDS1, CDS2 and CDS3 proteins are more similar to eukaryotic CDS than to prokaryote CDS, whilst CDS4 and CDS5 show the highest sequence similarity to the prokaryote, cyanobacteria. In addition, CDS4 and CDS5 contain cleavable N-terminal transit peptides for the import into plastids suggesting that CDS4 and CDS5 code for plastidial enzymes (plastids are derived from endosymbiotic cyanobacteria). CDS4 and CDS5 have redundant functions and only the double mutant shows a phenotype. Seedlings of the double mutant are not viable in soil, grow more slowly on agar-solidified medium with sucrose than wild-type plants, and develop yellow green leaves due to a reduction in chlorophyll. Although the size of the plastids in the double mutant are the same as wild type, there are severe defects in thylakoid structure. In the double mutant, PG biosynthesis is compromised and this is coupled to an increase in PA. PG is also required for the photosynthetic function contributing to the maintenance of chlorophyll-protein complexes in thylakoid membranes ([@B46]; [@B136]). In the cyanobacterium, *Synechocystis* sp. PCC6803, mutants defective in the CDS gene show a decrease in PG and growth is repressed which can be rescued by exogenous PG ([@B136]). The Cds protein is 293 amino acids and exhibits a 38% identity with that of *E. coli* Cds, and like the *E. coli* Cds, lacks a hydrophilic N-terminus commonly present in the eukaryotic CDSs ([Figure 2A](#F2){ref-type="fig"}).

CDS1 and CDS2 are constitutively expressed whilst CDS3 is only expressed in certain plant structures including stamens and mature pollens ([@B166]). Both CDS1 and CDS2 are located at the ER and single mutants lacking either CDS1 or CDS2 are viable but the double mutant is not indicating redundancy. After germination, the double mutants failed to develop leaves. The double mutant seedlings showed a dramatic increase in PA levels accompanied by a decrease in PI levels but no significant change in PG levels. In summary, whilst CDS4 and CDS5 supply CDP-DAG for the synthesis of PG in plastids, CDS1, and CDS2 supply CDP-DAG for the synthesis of PI. In plants, PG is also made in microsomes and therefore its levels were also reduced in the CDS1/CDS2 knockouts, whilst CL was not affected ([@B166]).

Cds in Apicomplexa {#S12}
==================

CDS proteins of *Plasmodium falciparum* and *Toxoplasma gondii* both belong to the phylum Apicomplexa. These CDS proteins possess a long N-terminal extension compared with other eukaryotic CDS proteins ([@B141]; [@B77]).

Plasmodium falciparum {#S13}
=====================

*Plasmodium falciparum* is a unicellular protozoan parasite and is the major cause of malaria in humans. *P. falciparum* require intense membrane synthesis when red cells are infected, and at this intraerythrocytic stage, glycerophospholipids originate from the *P. falciparum*-encoded machinery. Erythrocytes lack the machinery to make phospholipids. Synthesis of phospholipids in *P. falciparum* occurs through the same pathways as in higher eukaryotes. However, as in yeast, the malarial parasite has retained the prokaryotic system for PS synthesis from CDP-DAG. Synthesis of PI, the precursor for the polyphosphoinositides, is essential and the single CDS gene provides CDP-DAG for its synthesis.

The gene encoding CDS was isolated from *P. falciparum* based on sequence conservation to CDS from other organisms ([@B97]). Unlike other eukaryotic CDSs, *Pf*CDS is a large protein of 667 amino acids with a molecular weight of 78 kDa. Only the C-terminal 442 a.a. share 40% homology with eukaryotic CDSs. The long non-conserved N-terminal region of 245 a.a. is hydrophilic and cleaved during translation resulting in a 51 kDa protein that expresses CDS activity ([@B27]; [@B141]) and a 28 kDa fragment. The conserved C-terminal fragment of *Pf*CDS is sufficient for enzyme function but insufficient to rescue *P. knowlesi* when its endogenous CDS is deleted. Rescue can only be effected by the full-length protein. *P. knowlesi* contains a CDS enzyme of 640 a.a. and is characterized by the N-terminal long extension similarly to *P. falciparum*. *Pk*CDS is an essential gene for *P. knowlesi* blood stage parasites and could be rescued by *Pf*CDS despite the fact that the N-terminal extension between *Pf*CDS and *Pk*CDS has only 26% identity. The N-terminal extension of CDS was found to be essential as rescue was not achievable with the truncated form, which contains the CDS activity ([@B141]). Although the function of the cleaved 28 kDa fragment is not known, it is trafficked outside the parasite to the parasitophorous vacuole membrane.

Not all members of the Apicomplexa have long N-terminal extensions. It appears to be present in only those organisms that reside in their host cell with a parasitophorous vacuole, whereas CDS from other Apicocomplexa (e.g., *Babesia bovis*, *Theileria parva*, and *Crytosporidium parvum*) are similar to other eukaryotic CDS ([@B27]; [@B77]).

Toxoplasma gondii {#S14}
=================

*Toxoplasma gondii* is a protozoan parasite and replicates within a vacuole in nucleated cells of virtually all warm-blooded organisms. For replication, phospholipid synthesis is essential and CDP-DAG is a major precursor for phospholipid synthesis. In *T. gondii*, two phylogenetically divergent CDS enzymes are present ([@B77]). The eukaryotic type *Tg*Cds1 that resides in the ER and prokaryotic type *Tg*Cds2 that resides in the apicoplast. Unlike the enzymes in mammals, yeast or *Drosophila* which are approximately ∼450 a.a. long ([Figure 2A](#F2){ref-type="fig"}), *Tg*Cds1 and *Tg*Cds2 are just over 1000 a.a. due to an extensive N-terminal region ([@B77]). The apicoplast is a non-photosynthetic plastid-like organelle acquired by secondary endosymbiosis of red algae. *Tg*Cds2 orthologs have been identified in selected parasites such as *T. cruzi* and *L. major* but not in *P. falciparum* and *T. brucei* ([Table 1](#T1){ref-type="table"}). In *P. falciparum* and *T. brucei*, only one eukaryotic-type CDS has been identified. It should be noted that the mitochondrial CDS, TAMM41, is absent in protozoans ([@B77]).

*Tg*Cds1 and *Tg*Cds2 mutants are essential genes, and conditional knockout of *Tg*Cds1 impaired the synthesis of PI and PS, whilst knockdown of *Tg*Cds2 resulted in the selective impairment of PG. The mutants show severely reduced growth due to impaired replication and this could not be restored upon addition of exogenous lipids. The data suggests ER-derived CDP-DAG is utilized for PI synthesis in Golgi bodies, whilst CDP-DAG made in the apicoplast is utilized for making PG in mitochondria. Whilst apicoplasts can make PA, for PG synthesis CDP-DAG will have to be transferred to mitochondria where the enzymes are located. It is worth noting that membrane contact sites between the apicoplasts and the ER has been revealed by electron tomography in *T. gondii* ([@B152]). Lipid transfer proteins that can bind and transfer CDP-DAG from one membrane compartment to another have yet to be identified.

Eimeria falciformis {#S15}
===================

*Eimeria falciformis* is a mouse parasite with a complex lifestyle and undergoes the sporozoite stage that develops outside the host cells. Thus, the freely developing sporozite has to synthesize its own lipids. Phospholipid biogenesis is highly compartmentalized, spread primarily in the apicoplast, ER, mitochondrion and Golgi body. Like *T. gondii*, *E. falciformis* also contain two phylogenetically divergent CDS enzymes ([@B77], [@B76]; [Table 1](#T1){ref-type="table"}). The ER contains the eukaryotic type *Ef*Cds1 whilst the prokaryotic type *Ef*Cds2 localizes to the apicoplast. PIS, the enzyme that makes PI from CDP-DAG, localizes to the Golgi body requiring the lipid transfer of CDP-DAG from the ER to the Golgi body. Likewise, the CDP-DAG made in the apicoplast by *Ef*CDS2 needs to be transferred to the mitochondria where the machinery to make PG and CL are located ([@B76]). Clearly, a significant amount of inter-organelle trafficking of CDP-DAG is required predicting the presence of multiple membrane contact sites. In other Apicocomplexa, membrane contact sites between the ER, Golgi complex, apicoplast and mitochondrion have been identified ([@B152]).

Cds in the Kinetoplastid, *Trypanosoma brucei* {#S16}
==============================================

*Trypanosoma brucei*, the causative agent of African sleeping sickness, expresses a VSG coat for protection from the host immune system. The VSG forms dimers that are inserted in the outer leaflet of the PM by glycosylphosphatidylinositol (GPI) anchors. GPI anchors are dependent on CDP-DAG for their synthesis. *T. brucei* has a single gene for *Cds* ([@B84]). It is essential in the bloodstream form of the parasite. The *Tb*Cds conditional knockout shows morphological changes including a cell-cycle arrest due in part to kinetoplast segregation defects. Biochemical phenotyping of *Tb*CDS conditional knockout shows drastically altered lipid metabolism where reducing levels of PI detrimentally affected GPI biosynthesis. *Tb*CDS was shown to localize to the ER and Golgi, probably to provide CDP-DAG for PISs.

*Tb*CDS protein contains the typical CDS motif signature, and BLAST searches using typical prokaryotic CDS sequences recovered a putative second CDS gene in *T. cruzi*, *T. vivax*, and several *Leishmania* species, but not in *T. brucei*. All of these genes were more similar to the prokaryotic than the eukaryotic CDS genes. *T. Cruzi* appears to have lost its prokaryotic version of Cds that has been retained in other species ([Table 1](#T1){ref-type="table"}).

Discovery of Tam41/Tamm41 as Possessing Cds Activity {#S17}
====================================================

Synthesis of CL in mitochondria is well-established ([@B60]; [@B9]; [@B99]; [@B139]; [@B140]). Most of the key enzymes in the biosynthesis of CL, starting with PA, are characterized and are known to be localized in the matrix side of the inner mitochondrial membrane ([Figure 1](#F1){ref-type="fig"}). For CL synthesis, the first reaction is the conversion of PA and CTP to CDP-DAG, and it has been assumed in some studies that the enzyme responsible for this conversion are the ER-localized CDS enzymes, CDS1 and CDS2 ([@B80]; [@B83]). CDP-DAG is required for two steps in the synthesis of CL. In the first step, CDP-DAG is converted into PGP by the mitochondrial-localized enzyme, phosphatidylglycerol phosphate synthase (PGPS) ([@B75]; [@B34]; [@B71]). A PGP phosphatase dephosphorylates PGP to form PG by unrelated enzymes, Gep4 (in yeast) or PTPMT1 (in mammals) localized in mitochondria ([@B118]; [@B164]). Finally, a CL synthase (CLS), couples PG and another molecule of CDP-DAG to generate CL ([Figure 1](#F1){ref-type="fig"}). CL undergoes remodeling of its fatty acid chains by a CL-specific phospholipase A and tafazzin (TAZ1), an acyltransferase to the final mature form of CL whose acyl chains are predominantly C18:2 ([@B139]).

Uptake of newly synthesized mitochondrial proteins occur with the assistance of protein translocator complexes residing in the outer and inner mitochondrial membranes. In 2006, two studies in the yeast, *S. cerevisiae*, identified a mitochondrial protein that was required for the assembly and maintenance of the activity of the TIM23 complex. The protein was named Mmp37p (mitochondrial matrix protein of 37 kDa) ([@B37]) or Tam41 (translocator assembly and maintenance 41) ([@B151]). Tam41/Mmp37p was needed for the import of precursor proteins destined for the matrix and the inner membrane of the mitochondria via the TIM23 complex. Tam41 was characterized as a peripheral inner mitochondrial protein facing the matrix with homologs in many eukaryotic organisms. Tam41 was not part of the TIM23 complex, but was required for the maintenance and integrity of the TIM23 complex ([@B151]). Furthermore, the assemblies of ADP/ATP carrier, complex III, and complex IV were also disrupted in *tam41*Δ mitochondria ([@B79]).

Mitochondria lacking *Tam41* are temperature-sensitive for growth at elevated temperatures ([@B37]; [@B151]). Loss of *Tam41* revealed the lack of both PG and CL accompanied by an increase in PA in mitochondria ([@B79]). Not surprisingly, Tam41 was subsequently found to possess CDP-DAG synthase activity ([@B150]). Tam41 CDS activity was characterized using the purified protein; Tam41 from *S. cerevisiae* (*Sc*Tam41) shows maximal activity at pH 7--9, and requires divalent metal ions such as Mg^2+^, Mn^2+^, and Co^2+^. In mammals, CDS activity had been reported to be present in mitochondria ([@B105], [@B106]), and recent studies have identified the mitochondrial activity to be due to TAMM41, the human homolog of Tam41 ([@B14]). A decrease in CL and a decline in oxygen consumption is observed in TAMM41-siRNA-treated H9c2 cardiomyoblasts. In Type I diabetic patients, DNA methylation of 780 mitochondrial proteins was examined and the *TAMM41* gene was found to be highly methylated in individuals with end-stage renal disease. Increased methylation of *TAMM41* gene would act to repress gene transcription suggesting that loss of TAMM41 function may be linked with the development of kidney disease ([@B148]).

Recently, the structure of Tam41 from *Schizosaccharomyces pombe* (*Sp*Tam41) was reported ([@B68]). *Sp*Tam41 protein comprises 393 amino acid residues with a short mitochondrial pre-sequence at the N-terminal region ([Figure 2B](#F2){ref-type="fig"}). Enzyme activity is optimal at pH 7.5 and divalent cations are essential for activity. The structure reveals that *Sp*Tam41 contains a nucleotidyltransferase (NTase) domain (residues 28--189) resembling the canonical fold of other NTases ([@B78]). Residues 190--319 folds into a winged helix domain, commonly found in nucleic acid binding proteins such as helicases, transcription factors and nucleic-acid-modifying enzymes ([@B49]). CTP binds to an "L"-shaped pocket sandwiched between the NTase and the winged helix domains. CTP and PA bind sequentially and both must be bound to the enzyme before either product (pyrophosphate and CDP-DAG) is released ([Figure 3B](#F3){ref-type="fig"}). The protein that was crystallized lacked the 74 residues from the C-terminal region of *Sp*Tam41. However, bioinformatic analysis together with experiments revealed that *Sp*Tam41, like TAMM41, is tightly associated with membranes and can only be released upon treatment with Na~2~C0~3~ (pH 11) and this is due to a positively charged amphipathic helix at the C-terminal region ([Figure 3B](#F3){ref-type="fig"}; [@B14]; [@B68]).

Functional Analysis of Tamm41 in Zebrafish {#S18}
==========================================

Biosynthesis of PG and CL takes place in the matrix side of the inner mitochondrial membrane and requires CDP-DAG as a central liponucleotide intermediate ([Figure 1](#F1){ref-type="fig"}). The enzyme that makes PG and CL in mitochondria has been identified as Tam41/TAMM41 ([@B150]; [@B14]). During zebrafish development, TAMM41 is enriched in the developing heart, and knockout of *Tamm41* driven by CRISPR, causes abnormal heart development, specifically a defect in heart valve formation. TAMM41 participates in regulating heart valve formation through mediating PINK1-dependent mitophagy ([@B161]). Examination of mitochondria of cardiac myocytes by electron microscopy showed that the mitochondria were much larger and more elongated. This was also observed in a heart cell line, AC16. The hyper-fused mitochondria is a predominant feature of these TAMM41-deficient cells. Interestingly, the level of CL was the same in the wild type and the TAMM41-depleted zebrafish. An increase in *Cds1* and *Pgs1* was observed, suggesting that mitochondrial TAMM41 deficiency can be compensated by CDS1. CDS1 resides in the ER and as such would require the transfer of CDP-DAG from the ER to the mitochondria ([Figure 1](#F1){ref-type="fig"}).

To examine whether TAMM41 enzymatic activity was required for normal heart valve development, a mutant (Tamm41-D121A) was used in rescue experiments. In yeast, mutation of the residue D220A abolishes enzymatic activity; D121A is the corresponding mutation in zebrafish. Surprisingly, this mutant restored normal heart valve development indicating that CL biosynthesis was not required for this process. However, enzyme activity of the mutant protein was not analyzed.

In the *TAMM41*-deficient heart tissues that show increased numbers of enlarged mitochondria, mitochondrial proteins such as TOM20 and COXIV were increased. This was attributed to inhibition of PARK2-PINK1-dependent mitophagy. During mitophagy, PINK1 is stabilized at the mitochondrial membrane and phosphorylates the E3-ligase parkin (PARK2) which can then ubiquinate mitochondrial proteins. Silencing of *TAMM41* reduced the translocation of parkin thus reducing autophagy. TAMM41 interacted with PINK1 and stabilized PINK1 to allow mitophagy to take place. As the phenotype observed in zebrafish led to specific heart valve abnormalities, it was suggested that this was a tissue--specific role of *TAMM41* in heart development. It is noteworthy that TAMM41 is highly expressed in the developing heart.

Do Cds Enzymes Provide Cdp-Dag to Mitochondria for Phosphatidylglycerol/Cardiolipin Synthesis? {#S19}
==============================================================================================

One of the outstanding questions is the degree to which CDS1 and CDS2 contribute toward PG and CL synthesis. There is substantial evidence that both CDS1 and CDS2 can contribute to CL biosynthesis in heart ([@B80]). PGC-1 α and β are transcriptional regulators of mitochondrial metabolism and their loss in mouse heart causes a defect in CL biosynthesis resulting in mitochondrial ultrastructural abnormalities. The *CDS1* gene was downregulated whilst CDS2, PGS1, PTPMT1, and CLS1 mRNA were increased in PGC-1α/β^--/--^ mice. Importantly, the *CDS1* gene was shown to be a direct target for PGC-1α. The observation that CDS2 mRNA is increased together with the mRNA of the biosynthetic enzymes of the CL pathway suggests that CDS2 may contribute to CDP-DAG when CDS1 mRNA levels are reduced. No measurements of TAMM41 were done as the enzyme has not yet been identified.

Interestingly, CL content is also decreased in AMPKα2 knockout mice coupled to a decrease in CDS2 mRNA ([@B7]). The observation that knockout of different regulatory control mechanisms, i.e., PGC-1α/β or AMPKα2, can lead to a decrease in CL but is also linked to a decrease in CDS1 or CDS2 indicate that both CDS enzymes can contribute to CL synthesis. This would require mechanisms for transfer of CDP-DAG from the ER all the way to the inner membrane of the mitochondria crossing the outer membrane of the mitochondria and then transferred to the inner membrane ([Figure 1](#F1){ref-type="fig"}). Such lipid transporters have not yet been identified.

Studies in yeast, where *Tam41* is deleted, a small amount of CL synthesis does occur suggesting that the yeast *CdsA* can contribute CDP-DAG for CL synthesis. Importantly, a greater increase in CL was observed when inositol was depleted simultaneously. Depletion of inositol would inhibit consumption of CDP-DAG by PIS making the CDP-DAG available for transfer from the ER to the mitochondria. Exogenous addition of a fluorescent CDP-DAG (NBD-CDP-DAG) to mitochondria also resulted in conversion into metabolites that were dependent on the presence of Pgs1. This indicated that exogenously added NBD-CDP-DAG could be transported to the inner mitochondrial membrane.

In several studies it has been noted that knockdown of CDS enzymes cause not only a decrease in PI but also PG, again arguing for a mechanism for the ER to supply mitochondria with CDP-DAG ([@B88]; [@B81]; [@B125]; [@B77]). Close membrane contact sites between ER and mitochondria have been reported and this could provide a route for lipid transfer ([@B111], [@B112]; [@B38]; [@B59]; [@B70]). Other data also support the possibility that there is a pathway for CDP-DAG to traverse from the ER to the mitochondria. In *T. gondii*, there are two divergent CDS enzymes: the eukaryotic type, *Tg*Cds1, localized at the ER, and the prokaryotic type, *Tg*CDS2, localized at the apicoplast. Ablation of *TgCds2* resulted in the \>80% reduction in PG biosynthesis, whilst ablation of *TgCds1* resulted in a decrease in PI and PS ([@B77]). As *T. gondii* lack Tam41, the prokaryotic-type CDS, *Tg*Cds2, in the apicoplast appears to provide the CDP-DAG to mitochondria for PG synthesis. The CDP-DAG made by *Tg*Cds1 in the ER appears to also translocate to the Golgi where *Tg*PIS is located to make PI. In *A. thaliana*, the two prokaryotic-type CDSs, CDS4, and CDS5 are also required for PG synthesis in the plastids; however, these enzymes are predicted to contain cleavable N-terminal transit peptides for the import into plastids.

These data all point to the presence of lipid transfer proteins that could mediate the transfer of CDP-DAG between different membrane compartments. Lipid transfer proteins that can bind and transfer CDP-DAG have yet to be identified. There are many lipid transfer proteins where the bound lipid remains to be characterized ([@B21]; [@B157]). One potential candidate is the ER--mitochondria encounter structure (ERMES) complex found in yeast which are present at the ER- mitochondria contact sites ([@B2]). Three out of four ERMES complex proteins (Mmm1, Mdm12, and Mdm34) contain an SMP domain. The SMP domain can transport lipids by binding to the acyl chains of phospholipids rather than the headgroup. The ERMES complex is absent in mammals but a related protein, PDZD8, also contains an SMP domain and resides at ER-mitochondria contact sites ([@B57]).

Concluding Remarks {#S20}
==================

Cytidine diphosphate diacylglycerol occupies a critical branch point in the synthesis of two lipids, PI and CL. Both lipids play essential roles in many aspects of cell function including cell signaling and mitochondrial function. The synthesis of these two lipids is compartmentalized in different membranes; ER for PI synthesis and mitochondria for PG and CL synthesis. Thus, the identification of two unrelated families of enzymes with CDS activity, CDS and TAMM41, which localize in specific compartments, would obviates the need for the transfer CDP-DAG from the ER to mitochondria under normal circumstances.

Studies where CDS1 and CDS2 levels have been decreased reveal that the cellular consequences can vary dramatically. The consequences of inhibition cause accumulation of PA and a decrease in PI levels. Both have consequences for cells that are manifested in a context-specific manner. Increased PA levels cause defects in membrane function whilst the decrease in PI levels impacts on both PLC and PI3K signaling. Moreover, in some cells, PA does not accumulate and is redirected toward other pathways leading to increases in TAG and thus accumulation of lipid droplets.

In mammalian cells, it appears that CDS2 may be the enzyme that in involved is PLC signaling based on the phenotype observed in zebrafish and its selectivity for 18:0/C20:4-PA. However, in cultured H9c2 cells, CDS1 appears to be more relevant as this is upregulated during vasopressin signaling when PI levels are dramatically decreased. It is possible that when PI levels are substantially reduced, CDS1 is more important as the synthesis of PI would not be limited by the availability of 18:0/C20:4-PA. It is also becoming clear that the expression levels of CDS enzymes are regulated in different conditions ([Table 2](#T2){ref-type="table"}). Since the formation of CDP-DAG is the rate limiting step in the synthesis of PI, changes in the levels of CDS enzymes are likely to regulate many of the signaling pathways including PLC and PI3K. The amount of PI(4,5)P~2~ in cells will determine both the extent and duration of signaling and therefore regulation of CDS expression under physiological or pathological conditions will have major consequences. Whether CDS enzymes are regulated post-translationally is not known, but the identification of residues that are phosphorylated or ubiquitylated implies that this is likely to be the case. Identification of the enzymes responsible for these modifications will provide a better understanding on regulation of these enzymes.
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a.a.

:   amino acid

CarS

:   CDP-archeol synthase

CDP-DAG

:   CDP-diacylglycerol

CDS

:   CDP-diacylglycerol synthase

CL

:   cardiolipin

CLS

:   cardiolipin synthase

DAG

:   diacylglycerol

DAGK

:   diacylglycerol kinase

DGAT

:   diacylglycerol acyl transferase

DGGGP

:   2,3-bis-O-geranylgeranyl *sn*-glycerol-phosphate

ERR

:   estrogen-related receptor

GPAT

:   glycerol phosphate acyl transferase

I(1,4,5)P~3~

:   inositol (1,4,5) triphosphate

Lipin

:   PA phosphatase

LPA

:   lyso-PA

LPAAT

:   lysoPA acyl transferase

LPIAT1

:   lyso-phosphatidylinositol acyltransferase 1

NBD

:   \[(7-nitro-2-1,3-benzoxadiazol-4-yl) amino\]

PA

:   phosphatidic acid

PC

:   phosphatidylcholine

PE

:   phosphatidylethanolamine

PG

:   phosphatidylglycerol

PGC-1 α / β

:   peroxisome proliferator-activated receptor γ-coactivator

PGP

:   phosphatidylglycerol phosphate

PGPS

:   PGP synthase

PI(3,4,5)P~3~

:   phosphatidylinositol (3,4,5)P~3~

PI(4)P

:   phosphatidylinositol (4) phosphate

PI(4,5)P~2~

:   phosphatidylinositol (4,5) bisphosphate

PI

:   phosphatidylinositol

PI3K

:   phosphoinositide 3-kinase

PIS

:   phosphatidylinositol synthase

PKC

:   protein kinase C

PLC

:   phospholipase C

PLD

:   phospholipase D

PM

:   plasma membrane

PPAR γ

:   peroxisome proliferator-activated receptor γ

PS

:   phosphatidylserine

PTPMT1

:   protein tyrosine phosphatase mitochondrial 1

SIRT6

:   sirtuin 6

TAG

:   triacylglycerol

Tam41, translocator assembly and maintenance protein

:   41 kDa

TAMM41

:   mammalian Tam41

VEGFA

:   vascular endothelial growth factor A

VSG

:   variant surface glycoprotein.
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